埃特拉西莫德:用于性结肠炎的下一代S1P受体调节器 - 机械洞察力和临床进展
Manoj R Kumbhare1, Arshad S Shaikh1, Bhagwan R Ide1
1Department of Pharmaceutical Chemistry, SMBT College of Pharmacy (affiliated with Savitribai Phule Pune University), Dhamangaon, Nashik, Maharashtra 422403, India.
概括
埃特拉西莫德是一种新型的口服斯芬戈-1-酸盐 (S1P) 受体调节剂,通过降低风险减少炎症来治疗性结肠炎 (UC) 是有前途的. 临床试验证明了其在改善缓解和愈合方面的有效性,为患者提供了友好的选择.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 免疫媒介性炎症性疾病 (IMIDs),如性结肠炎 (UC),需要有效的治疗方法.
- 选择性基-1-酸盐 (S1P) 受体调节器为免疫调节提供了有针对性的方法.
- 第一代S1P调制器在安全性和患者遵守性方面存在局限性.
研究的目的:
- 评估etrasimod,一个下一代S1P受体调节器,作为治疗中度至重度UC.
- 与现有疗法相比,评估埃特拉西莫德的安全性,疗效和药物动力学概况.
- 探索埃特拉西莫德在治疗其他IMID中的潜力.
主要方法:
- 进行了临床试验 (ELEVATE UC 12和ELEVATE UC 52),以评估埃特拉西莫德的疗效.
- 埃特拉西莫德的机制涉及对S1PR1,S1PR4和S1PR5的作用,以保留淋巴细胞.
- 与安慰剂和第一代S1P调节器进行了比较.
主要成果:
- 在UC患者中,Etrasimod在临床缓解和粘膜愈合方面显著改善.
- 该药物表现出有利的安全性和药理动力学特征.
- 短暂的洗期和每天一次的口服剂量可以提高患者的坚持和方便性.
结论:
- 埃特拉西莫德代表了UC管理的重大进步,提供有针对性的免疫调节.
- 其有利的安全性和有效性概况表明,它有可能在其他IMID中得到更广泛的应用.
- 口服,每天服用一次的配方改善了患者友好性和治疗坚持.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
519
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
519
Inflammatory Bowel Disease I: Ulcerative Colitis
991
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
991
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
596
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
596
Internal Receptors
74.7K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.7K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
998
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
998
Peptic Ulcer Disease II: Pathophysiology
2.1K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.1K


